Venous Thromboembolism
Conditions
Keywords
Non-interventional Study, Real World Evidence, Patients with Acute VTE treated with Edoxaban, Efficacy/Safety
Brief summary
According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are limited to a maximum treatment duration of 12 months. Therefore, this study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality and other drug related adverse events) of extended treatment with edoxaban up to 12 months in an unselected patient population in routine clinical practice.
Detailed description
Edoxaban is an orally administered anticoagulant that inhibits coagulation factor Xa. It has been approved by the Ministry of Food and Drug Safety (MFDS) in Korea (date: 25th, August 2015) for the: Reduction in the risk of stroke and systemic embolism in patients with non valvular atrial fibrillation (NVAF) Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) Reduction in the risk of recurrent DVT and PE, and by Taiwan Food and Drug Administration (TFDA) in Taiwan (date: 24th, February, 2016) for the Prevention of stroke and systemic embolism in adult patients with NVAF with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant. According to current guidelines, duration of anticoagulant treatment after a venous thromboembolic event varies from 3 months to indefinite treatment depending on the estimated risks of venous thromboembolism (VTE) recurrence and bleeding. Current data for edoxaban are limited to a maximum treatment duration of 12 months. This non-interventional study aims to gather further insight into efficacy (i.e. symptomatic recurrent VTE) and safety (i.e. bleeding events, liver adverse events, all-cause mortality and other drug related adverse events) of extended treatment with edoxaban up to 12 months in approximately 350 patients in an unselected patient population in routine clinical practice.
Interventions
DRUGEdoxaban
Prescribed according to approved label
Sponsors
Daiichi Sankyo
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Established acute initial or recurrent VTE * Patients prescribed treatment with edoxaban according to package information before participation in the trial * Written informed consent for participation in the study (ICF) * Not simultaneously participating in any interventional study
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Rate of overall symptomatic VTE recurrence | Baseline to 12 months | Rate of overall symptomatic VTE recurrence within 12 months |
| Rate of participants experiencing Real World Safety Data Events | 12 months | Categories: VTE-related bleeding events, Drug-related adverse events, Cardiovascular Mortality, and All-cause Mortality |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of participants taking edoxaban with symptomatic VTE recurrence | 12 months | Rate of participants taking edoxaban with symptomatic VTE recurrence in 12 months |
| Rate of participants who permanently discontinued edoxaban with symptomatic VTE recurrence | 12 months | Rate of participants who permanently discontinued edoxaban with symptomatic VTE recurrence in 12 months |
| Rate of participants with patient relevant outcomes | 12 months | Patient relevant outcomes include bleeding events, strokes (ischaemic and haemorrhagic), systemic embolic events (SEE), and hospitalisations related to cardiovascular (CV) condition (including VTE related hospitalisation). |
Countries
South Korea, Taiwan
Outcome results
None listed